Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2005
The primary objective of this study is to compare the efficacy and safety of 3 dose levels of oral ERB-041 administered daily for 12 weeks versus placebo in subjects with active rheumatoid arthritis who have had a suboptimal response to therapy with stable doses of methotrexate (MTX).
Epistemonikos ID: 6d267b36f93987452ed7bf24846aeddb60504296
First added on: Mar 23, 2022